Our Science – Beutler Website
John A. Beutler, Ph.D.
MSc Phila College of Pharmacy & Science 1978
PhD Phila College of Pharmacy & Science 1980
We are advancing two natural product projects towards the clinic: englerins for kidney cancer and Ewings sarcoma, and schweinfurthins for CNS tumors and other NF1-dependent conditions. These natural products both have unique mechanisms of action. In addition, our group builds and maintains the library of chemical diversity with which the MTL conducts high throughput screening campaigns based on CCR-identified molecular targets.
J. G. Kodet, J. A. Beutler, and D. F. Wiemer. Synthesis and structure activity relationships of schweinfurthin indoles. Bioorg.Med.Chem. 2014.(In Press)
S. J. Lockett, C. Cui, P. Gudla, K. Nandy, Y. Mimaki, P. L. Fuchs, J. Jaja, K. M. Reilly, J. A. Beutler, and T. J. Turbyville. Quantitative analysis of F-actin redistribution in astrocytoma cells treated with candidate pharmaceuticals. Cytometry A 2014.(In Press)
C. Sourbier, B. T. Scroggins, R. Ratnayake, T. L. Prince, S. Lee, J. M. Lee, J. B. Trepel, J. A. Beutler, W. M. Linehan, and L. M. Neckers. Englerin A stimulates PKC theta to inhibit insulin signaling while simultaneously activating HSF1: A case of pharmacologically induced synthetic lethality. Cancer Cell 23 (2):228-237, 2013.
T. J. Turbyville, D. B. Gursel, R. G. Tuskan, J. C. Walrath, C. Lipshutz, S. J. Lockett, D. F. Wiemer, J. A. Beutler, and K. M. Reilly. Schweinfurthin A selectively inhibits proliferation and Rho signaling in glioma and neurofibromatosis type 1 tumor cells in an NF1-GRD dependent manner. Mol.Cancer Ther. 9 (5):1234-1243, 2010.
M. R. Boyd, C. Farina, P. Belfiore, S. Gagliardi, J. W. Kim, Y. Hayakawa, J. A. Beutler, T. C. McKee, B. J. Bowman, and E. J. Bowman. Discovery of a novel antitumor benzolactone enamide class that selectively inhibits mammalian vacuolar-type (H+)-ATPases. J.Pharmacol.Exp.Ther. 297 (1):114-120, 2001.
This page was last updated on 3/5/2014.